Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Subjects With DSM-5 Schizophrenia

NCT04659174 is registered in ClinicalTrials.gov with Karuna Therapeutics, Inc., a Bristol Myers Squibb company as lead sponsor.

NCT NCT04659174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04659174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Subjects With DSM-5 Schizophrenia
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase
Phase 3
Overall status
Completed
Start date
February 1, 2021
Completion date
October 3, 2023
Enrollment
152 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia